UBP 282

Discontinued Product

UBP 282 (Cat. No. 1765) has been withdrawn from sale for commercial reasons.
Description: Non-NMDA iGluR antagonist; distinguishes between motoneuron and dorsal root kainate receptors
Alternative Names: 3-CBW
Chemical Name: (αS)-α-Amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinepropanoic acid
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for UBP 282

AMPA and kainate receptor antagonist. Inhibits AMPA receptor-, but not kainate receptor-mediated currents on spinal neonatal motoneurons yet antagonizes kainate-induced responses on dorsal root C-fibres.

Technical Data for UBP 282

M. Wt 333.3
Formula C15H15N3O6
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 544697-47-4
PubChem ID 6604912
InChI Key XLRLZPOBHPIDFX-NSHDSACASA-N
Smiles O=C(C=CN1C[C@H](N)C(O)=O)N(CC2=CC=C(C(O)=O)C=C2)C1=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for UBP 282

References are publications that support the biological activity of the product.

More et al (2002) The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres. Br.J.Pharmacol. 137 1125 PMID: 12429586

More et al (2003) Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br.J.Pharmacol. 138 1093 PMID: 12684265

View Related Products by Product Action

View all AMPA Receptor Antagonists

Keywords: UBP 282, UBP 282 supplier, AMPA/kainate, antagonists, receptors, Glutamate, AMPA, iGluR, Ionotropic, Kainate, UBP282, 3CBW, 3-CBW, Receptors, 1765, Tocris Bioscience

Citations for UBP 282

Citations are publications that use Tocris products.

Currently there are no citations for UBP 282.

Reviews for UBP 282

There are currently no reviews for this product. Be the first to review UBP 282 and earn rewards!

Have you used UBP 282?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.